What Stakeholders Can Do to Drive Clinical Research on Rare Cancers

Medical Practice / Clinical Research







EONS

- European Oncology Nursing Society
- Represents 31 member societies, 28 European countries
 - Established in 1984
 - Promote practice of cancer nursing
 - Educational, research and practice-based initiatives
- Nurses represent approx. 33 % of the healthcare work force
- have the most contact with patients throughout all phases of the cancer journey



Awareness

- Rare Cancers can be addressed
 - by disseminating information to nurses where such cancers can be treated
 - in continuing education courses for nurses throughout Europe
 - in palliative settings where many of the patients will be cared for



Role of nurses in clinical trials

What we do, we can do

 Nurses can be of influence in the development and review of clinical trials.



Depending on the country, institution, internal structures:

- Nurses can
 - participate in the trial review board (is it feasible in the clinical setting?)
 - be involved in the recruitment of patients
 - help determine if the informed consent clearly formulated
 - can take a position about the number of test planned (acceptable for the patient?)



And as well can ...

- take an active part guiding the patients, carers understanding the protocol,
- support to understand ethical questions,
- help understand complicated therapy regimens
- educate patients about side effects of drugs and their management
- help patients and carers understand changes in daily matters
- encourage contact with special patient support groups



 Integrate nursing sub-studies within a trial to enhance the supportive care issues accompanying trial therapies



Integrate existing symptom management guidelines



- consult and give information for patients carers re. selfmanagement of taking drugs
- Nurses can help raise the compliance/adherence of the patients to continue in a study







www.cancernurse.eu

Raising Awareness

Communication-Newsletter & Website

